Characterization of a novel venetoclax resistance mutation (BCL2 Phe104Ile) observed in follicular lymphoma

被引：40
作者：
Blombery, Piers [1 ,2 ,3 ,4 ]
Birkinshaw, Richard W. [5 ,6 ]
Nguyen, Tamia [1 ,4 ]
Gong, Jia-nan [5 ,6 ]
Thompson, Ella R. [1 ,4 ]
Xu, Zhen [5 ,6 ]
Westerman, David A. [1 ,2 ,3 ,4 ]
Czabotar, Peter E. [5 ,6 ]
Dickinson, Michael [2 ,3 ,4 ]
Huang, David C. S. [5 ,6 ]
Seymour, John F. [2 ,3 ,4 ]
Roberts, Andrew W. [2 ,3 ,5 ,6 ,7 ,8 ]
机构：
[1] Peter MacCallum Canc Ctr, Dept Pathol, Melbourne, Vic, Australia
[2] Peter MacCallum Canc Ctr, Clin Haematol, Melbourne, Vic, Australia
[3] Royal Melbourne Hosp, Melbourne, Vic, Australia
[4] Univ Melbourne, Sir Peter MacCallum Dept Oncol, Melbourne, Vic, Australia
[5] Walter & Eliza Hall Inst Med Res, Melbourne, Vic, Australia
[6] Univ Melbourne, Dept Med Biol, Melbourne, Vic, Australia
[7] Univ Melbourne, Ctr Canc Res, Melbourne, Vic, Australia
[8] Victorian Comprehens Canc Ctr, Melbourne, Vic, Australia
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 2019年 / 186卷 / 06期
关键词：
BCL2; lymphomas; genetic analysis;
D O I：
10.1111/bjh.16069
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：E188 / E191
页数：4
相关论文
共 10 条
  • [1] Dynamic molecular monitoring reveals that SWI-SNF mutations mediate resistance to ibrutinib plus venetoclax in mantle cell lymphoma
    Agarwal, Rishu
    Chan, Yih-Chih
    Tam, Constantine S.
    Hunter, Tane
    Vassiliadis, Dane
    Teh, Charis E.
    Thijssen, Rachel
    Yeh, Paul
    Wong, Stephen Q.
    Ftouni, Sarah
    Lam, Enid Y. N.
    Anderson, Mary Ann
    Pott, Christiane
    Gilan, Omer
    Bell, Charles C.
    Knezevic, Kathy
    Blombery, Piers
    Rayeroux, Kathleen
    Zordan, Adrian
    Li, Jason
    Huang, David C. S.
    Wall, Meaghan
    Seymour, John F.
    Gray, Daniel H. D.
    Roberts, Andrew W.
    Dawson, Mark A.
    Dawson, Sarah-Jane
    [J]. NATURE MEDICINE, 2019, 25 (01) : 119 - +
  • [2] Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia
    Blombery, Piers
    Anderson, Mary Ann
    Gong, Jia-nan
    Thijssen, Rachel
    Birkinshaw, Richard W.
    Thompson, Ella R.
    Teh, Charis E.
    Nguyen, Tamia
    Xu, Zhen
    Flensburg, Christoffer
    Lew, Thomas E.
    Majewski, Ian J.
    Gray, Daniel H. D.
    Westerman, David A.
    Tam, Constantine S.
    Seymour, John F.
    Czabotar, Peter E.
    Huang, David C. S.
    Roberts, Andrew W.
    [J]. CANCER DISCOVERY, 2019, 9 (03) : 342 - 353
  • [3] BCL2 mutations are associated with increased risk of transformation and shortened survival in follicular lymphoma
    Correia, Cristina
    Schneider, Paula A.
    Dai, Haiming
    Dogan, Ahmet
    Maurer, Matthew J.
    Church, Amy K.
    Novak, Anne J.
    Feldman, Andrew L.
    Wu, Xiaosheng
    Ding, Husheng
    Meng, X. Wei
    Cerhan, James R.
    Slager, Susan L.
    Macon, William R.
    Habermann, Thomas M.
    Karp, Judith E.
    Gore, Steven D.
    Kay, Neil E.
    Jelinek, Diane F.
    Witzig, Thomas E.
    Nowakowski, Grzegorz S.
    Kaufmann, Scott H.
    [J]. BLOOD, 2015, 125 (04) : 658 - 667
  • [4] Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
    Davids, Matthew S.
    Roberts, Andrew W.
    Seymour, John F.
    Pagel, John M.
    Kahl, Brad S.
    Wierda, William G.
    Puvvada, Soham
    Kipps, Thomas J.
    Anderson, Mary Ann
    Salem, Ahmed Hamed
    Dunbar, Martin
    Zhu, Ming
    Peale, Franklin
    Ross, Jeremy A.
    Gressick, Lori
    Desai, Monali
    Kim, Su Young
    Verdugo, Maria
    Humerickhouse, Rod A.
    Gordon, Gary B.
    Gerecitano, John F.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (08) : 826 - 833
  • [5] Acquired mutations in BCL2 family proteins conferring resistance to the BH3 mimetic ABT-199 in lymphoma
    Fresquet, Vicente
    Rieger, Melissa
    Carolis, Carlo
    Garcia-Barchino, Maria J.
    Martinez-Climent, Jose A.
    [J]. BLOOD, 2014, 123 (26) : 4111 - 4119
  • [6] Microenvironmental agonists generate de novo phenotypic resistance to combined ibrutinib plus venetoclax in CLL and MCL
    Jayappa, Kallesh D.
    Portell, Craig A.
    Gordon, Vicki L.
    Capaldo, Brian J.
    Bekiranov, Stefan
    Axelrod, Mark J.
    Brett, L. Kyle
    Wulfkuhle, Julia D.
    Gallagher, Rosa I.
    Petricoin, Emanuel F.
    Bender, Timothy P.
    Williams, Michael E.
    Weber, Michael J.
    [J]. BLOOD ADVANCES, 2017, 1 (14) : 933 - 946
  • [7] Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed/refractory MM
    Moreau, Philippe
    Chanan-Khan, Asher
    Roberts, Andrew W.
    Agarwal, Amit B.
    Facon, Thierry
    Kumar, Shaji
    Touzeau, Cyrille
    Punnoose, Elizabeth A.
    Cordero, Jaclyn
    Munasinghe, Wijith
    Jia, Jia
    Salem, Ahmed Hamed
    Freise, Kevin J.
    Leverson, Joel D.
    Enschede, Sari Heitner
    Ross, Jeremy A.
    Maciag, Paulo C.
    Verdugo, Maria
    Harrison, Simon J.
    [J]. BLOOD, 2017, 130 (22) : 2392 - 2400
  • [8] Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models
    Punnoose, Elizabeth A.
    Leverson, Joel D.
    Peale, Franklin
    Boghaert, Erwin R.
    Belmont, Lisa D.
    Tan, Nguyen
    Young, Amy
    Mitten, Michael
    Ingalla, Ellen
    Darbonne, Walter C.
    Oleksijew, Anatol
    Tapang, Paul
    Yue, Peng
    Oeh, Jason
    Lee, Leslie
    Maiga, Sophie
    Fairbrother, Wayne J.
    Amiot, Martine
    Souers, Andrew J.
    Sampath, Deepak
    [J]. MOLECULAR CANCER THERAPEUTICS, 2016, 15 (05) : 1132 - 1144
  • [9] Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
    Roberts, Andrew W.
    Davids, Matthew S.
    Pagel, John M.
    Kahl, Brad S.
    Puvvada, Soham D.
    Gerecitano, John F.
    Kipps, Thomas J.
    Anderson, Mary Ann
    Brown, Jennifer R.
    Gressick, Lori
    Wong, Shekman
    Dunbar, Martin
    Zhu, Ming
    Desai, Monali B.
    Cerri, Elisa
    Enschede, Sari Heitner
    Humerickhouse, Rod A.
    Wierda, William G.
    Seymour, John F.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2016, 374 (04) : 311 - 322
  • [10] Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study
    Seymour, John F.
    Ma, Shuo
    Brander, Danielle M.
    Choi, Michael Y.
    Barrientos, Jacqueline
    Davids, Matthew S.
    Anderson, Mary Ann
    Beaven, Anne W.
    Rosen, Steven T.
    Tam, Constantine S.
    Prine, Betty
    Agarwal, Suresh K.
    Munasinghe, Wijith
    Zhu, Ming
    Lash, L. Leanne
    Desai, Monali
    Cerri, Elisa
    Verdugo, Maria
    Kim, Su Young
    Humerickhouse, Rod A.
    Gordon, Gary B.
    Kipps, Thomas J.
    Roberts, Andrew W.
    [J]. LANCET ONCOLOGY, 2017, 18 (02) : 230 - 240
1